Items Tagged ‘CDK’

March 12, 2018

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases […]

View full entry

Tags: 4 & 6, Breast Cancer, CDK, inhibitor of cyclin-dependent kinases, News, Verzenio


October 30, 2017

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

By

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

View full entry

Tags: 4 & 6 inhibitor, abemaciclib, advanced breast cancer, Breast Cancer, CDK, cyclin-dependent kinase, News, Phase 3 MONARCH 2, Precision Cancer Medicine, Verzenio